Herceptin CMR
Research type
Research Study
Full title
Improving cardiac surveillance in patients undergoing chemotherapy.
IRAS ID
289253
Contact name
Peter Swoboda
Contact email
Sponsor organisation
University of Leeds
Clinicaltrials.gov Identifier
n/a, n/a
Duration of Study in the UK
10 years, 0 months, 1 days
Research summary
Each year many thousands of patients with cancer are treated with potentially cardiotoxic chemotherapy, An example of one commonly used is Herceptin in the treatment of Breast Cancer. Each patient undergoes surveillance scans to monitor their cardiac function. In Mid Yorkshire trust this is done with cardiac MRI Scanning.
The MRI image data included in this study will be from patients who are having the MRI as part of their routine clinical care whilst they receive treatment with Herceptin. These scans are jointly reviewed and reported by a consultant cardiologist and Radiologist with reports issues to patients and the treating clinical team. As such, the results gained from this study will not be used to determine direct patient care. No added scans or tests will be conducted as part of this study.
Scan data will be anonymised before analysis and will then be analysed by artificial intelligence (AI) algorithms to assess left and right ventricular size and function. We will establish whether the AI algorithm can identify those patients who have a clinically relevant deterioration in cardiac function.
The results gained from the AI platform will be compared with that of standard reporting measures for CMR and clinical outcomes, such as cessation of chemotherapy or initiation of heart failure medication. The long-term aim is to develop an end-to-end platform which can analyse and identify patients at risk of cardiac deterioration, without the need for any other user input. We will also collect baseline demographic data and conduct follow up by review of electronic records for up to 5 years.REC name
East of England - Cambridge East Research Ethics Committee
REC reference
20/EE/0299
Date of REC Opinion
12 Jan 2021
REC opinion
Further Information Favourable Opinion